The understanding of cancer's genetic basis has revolutionized oncology, paving the way for personalized medicine.  Early research, focusing on chromosomal abnormalities like the Philadelphia chromosome in chronic myeloid leukemia (CML), laid the groundwork for targeted therapies.  The subsequent Human Genome Project and advancements in high-throughput sequencing technologies significantly accelerated this progress, revealing the complex interplay of oncogenes, tumor suppressor genes, and DNA repair pathways in carcinogenesis.  Somatic mutations, specific to cancerous cells, are now routinely identified through techniques like next-generation sequencing (NGS), informing treatment strategies.

This genetic understanding fuels personalized medicine by allowing for the stratification of patients based on their tumor's unique molecular profile.  For instance, identifying EGFR mutations in lung cancer allows for the targeted application of EGFR tyrosine kinase inhibitors, offering significantly improved outcomes compared to traditional chemotherapy.  However, challenges remain, including the identification of actionable mutations, managing treatment resistance driven by secondary mutations, and addressing the heterogeneity within and between tumors.  Ongoing research focuses on improving diagnostic accuracy, developing novel targeted therapies, and integrating genomic data with clinical and lifestyle factors for truly individualized cancer care.